Caficrestat

DB15121InvestigationalSmall molecule

AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).

Mechanism: Pharmacologically active on Aldo-keto reductase family 1 member B1
Curator reviewed
Formula / weight: C₁₇H₁₀F₃N₅O₃S · 421.35 g/mol (avg)
Code names: AT-001

Resolves to

Compound

Structure

InChIKeyYRGPAXAVTDMKDK-UHFFFAOYSA-NSMILESOC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C2=C1N=CC=N2

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Caficrestat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.